Cited by 32Sexual function and dysfunction studiesPharmacovigilance and Adverse Drug ReactionsTreatment of Major Depression

Citizen petition: Sexual side effects of SSRIs and SNRIs

Open access
Healy, David·2018·International Journal of Risk & Safety in Medicine

Abstract

The undersigned submits this petition to request the Commissioner of Food and Drugs to immediately require the addition of boxed warnings, warnings, precautions, and highlights of prescribing information to the product label for all selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) products, including branded and generic formulations.These include, but are not limited to, citalopram (Celexa), desvenlafaxine (Pristiq), duloxetine (Cymbalta), escitalopram (Lexapro), fl uoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), venlafaxine (Effexor), and vortioxetine (Trintellix). A. Action requestedRequire the immediate revision of all SSRI and SNRI product labels (including branded and generic formulations) to warn of serious and severe risks, as follows: 1. Add WARNINGS, PRECAUTIONS, and HIGHLIGHTS OF PRESCRIBING INFORMATION to inform that the use of and withdrawal from SSRIs and SNRIs can result in genital anesthesia, pleasureless or weak orgasm, delayed or absent orgasm, loss of libido, erectile dysfunction, decreased vaginal lubrication, reduced nipple sensitivity, fl accid glans penis during erection, reduced response to sexual stimuli, and decreased capacity to experience sexual pleasure.2. Add WARNINGS, PRECAUTIONS, and HIGHLIGHTS OF PRESCRIBING INFORMATION to inform that the use of and withdrawal from SSRIs and SNRIs can result in persistent genital arousal disorder (PGAD).3. Add WARNINGS, PRECAUTIONS, HIGHLIGHTS OF PRESCRIBING INFORMATION, and a BOXED WARNING to inform that sexual side effects can sometimes persist for years or indefi nitely after discontinuation of the drug; they can emerge on treatment and remain afterwards, or emerge or worsen when the drug is stopped.4. Send all manufacturers of SSRIs and SNRIs a notifi cation letter of the need for a Risk Evaluation and Mitigation Strategy Plan to include the following: i. Require manufacturers to send a Dear Health Care Provider Letter to psychiatrists, psychologists, internists, family practitioners, urologists and endocrinologists that informs the health care providers that the drug has serious adverse reactions associated with its use, and poses a signifi cant public health concern.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jrs-180745

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Healy, D.
Affiliations
Data Based Medicine Americas Ltd., 95 Sandringham Drive, Toronto, Ontario, Canada, M3H 1E1.
Corresponding author
Healy, David
Venue
International Journal of Risk & Safety in Medicine
Published
2018-08
Volume
29
Issue
3-4
Pages
135-147
ISSN
  • 0924-6479 (ISSN-L)
  • 1878-6847
OpenAlex
W2799677170
Cited by
32
References
53
Citations by year
2025: 2 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 7
FWCI
2.56
Type
journal article
Language
en
Open access
Locations
  • International Journal of Risk & Safety in Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, sexual side effects, antidepressant side effects, persistent genital arousal disorder, drug withdrawal, drug labeling, black box warning, risk evaluation and mitigation strategy, prescribing information
MeSH terms
Serotonin and Noradrenaline Reuptake Inhibitors, Female, Humans, Libido, Male, Sexual Dysfunction, Physiological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review